Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arepanrix H1N1 Vaccine in Elderly Japanese Adults
NCT01114620Phase 4Completed
- Sponsor
- GSK
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant influenza ha vaccine (h5n1) in influenza, sponsored by GSK. Primary endpoints: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies at Day 182, Number of Seroprotected Subjects for HI Antibodies at Day 182 and 1 more. Started May 2010; status: completed.
02
Drugs
recombinant influenza ha vaccine (h5n1)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01114620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01114620.